Author

Hunter Levis

University of UtahORCID 0000-0002-1720-6545Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell signaling & trafficking· 2 Research Focus:cell type annotation· 2 Approach:genetic perturbation / CRISPR· 2 Organism:human· 2 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

Christian J. LewisiD· 2 shared Robby D. Bowles· 2 shared Sarah E. GullbrandiD· 2 shared Ameerah LawaliD· 1 shared Brandon Douglas LawrenceiD· 1 shared Brian O. DiekmaniD· 1 shared Elise StockhamiD· 1 shared Jacob D. WestoniD· 1 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBioengineering

Christian J. LewisORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

BioengineeringAging CellPeer-reviewedOct 1, 2026

ZNF865 (BLST) Regulates Back Pain via Cell Senescence and DNA Damage Mechanisms

Christian J. Lewis, Hunter Levis, Jonah Holbrook…·Robby D. Bowles

This study identifies ZNF865 as a regulator of cell senescence and DNA damage in intervertebral discs, showing its role in back pain and potential as a therapeutic target.

DOI 10.1111/acel.70754

humanmouse

𝕏 PostBluesky

BioengineeringActa BiomaterialiaPeer-reviewedNov 8, 2024

ZNF865 Regulates Senescence and Cell Cycle for Applications to Cell Engineering and Gene Therapy

Hunter Levis, Christian Lewis, Matthew Fainor…·Robby D. Bowles

This study identifies ZNF865 as a regulator of senescence and cell cycle, demonstrating its potential for cell engineering and gene therapy applications.

14 citationstop 5%

humangenetic perturbation / CRISPR

𝕏 PostBluesky